These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 6119712)

  • 21. [Complete neuroleptic withdrawal in patients with schizophrenia with intense symptoms and resistant to treatment].
    Wolf MA; Bailly L; Diener JM; Martinet JP; Peretti S; Garneau Y
    Encephale; 1991; 17(4):255-61. PubMed ID: 1683626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Neuroleptic modification of basic schizophrenic disorders].
    Heim M; Morgner J
    Psychiatr Neurol Med Psychol (Leipz); 1987 May; 39(5):274-80. PubMed ID: 2888144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Predictors of the course of schizophrenic diseases under neuroleptic long-term medication (author's transl)].
    Gaebel W; Pietzcker A; Poppenberg A
    Pharmacopsychiatria; 1981 Sep; 14(5):180-8. PubMed ID: 6117091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
    Reschke RW
    Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Drug treatment of schizophrenic psychoses in puerperium].
    Olbrich HM; Martin P
    Nervenarzt; 1994 Jul; 65(7):482-5. PubMed ID: 7800093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The "neuroleptic threshold"--a review of the literature].
    Abraham D; Kissling W; Lauter H
    Psychiatr Prax; 1996 May; 23(3):109-16. PubMed ID: 8710999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential effects of a new dibenzo-epine neuroleptic compared with haloperidol. Results of an open and crossover study.
    Mann K; Bartels M; Gärtner HJ; Schied HW; Wagner W; Heimann H
    Pharmacopsychiatry; 1987 Jul; 20(4):155-9. PubMed ID: 2886997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Information processing and neuroleptic response in acute and stabilized schizophrenic patients.
    Marder SR; Asarnow RF; Van Putten T
    Psychiatry Res; 1984 Sep; 13(1):41-9. PubMed ID: 6151203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A longitudinal study of cerebrospinal fluid angiotensin-converting enzyme in neuroleptic-treated schizophrenia.
    Wahlbeck K; Ahokas A; Nikkilä H; Miettinen K; Rimón R
    Prog Neuropsychopharmacol Biol Psychiatry; 1997 May; 21(4):591-9. PubMed ID: 9194142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroleptic treatment is an unlikely cause of elevated dopamine in thalamus of schizophrenic subjects.
    Oke AF; Putz C; Adams RN; Bird ED
    Psychiatry Res; 1992 Dec; 45(4):203-8. PubMed ID: 1363335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug therapy in schizophrenia--variability of outcome and prediction of response.
    Awad AG
    Can J Psychiatry; 1989 Oct; 34(7):711-20. PubMed ID: 2572318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No correlation between neuroleptic-induced increase of beta-endorphin serum level and therapeutic efficacy in schizophrenia.
    Naber D; Nedopil N; Eben E
    Br J Psychiatry; 1984 Jun; 144():651-3. PubMed ID: 6146374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy.
    Müller N; Hofschuster E; Ackenheil M; Eckstein R
    Acta Psychiatr Scand; 1993 Jan; 87(1):66-71. PubMed ID: 8093825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients.
    Harvey PD; Putnam KM; Davidson M; Kahn RS; Powchik P; McQueeney R; Keefe RS; Davis KL
    Psychiatry Res; 1991 Sep; 38(3):285-92. PubMed ID: 1684442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multidimensional study of the outcome of schizophrenic patients 1 year after clinic discharge. Predictors and influence of neuroleptic treatment.
    Gaebel W; Pietzcker A
    Eur Arch Psychiatry Neurol Sci; 1985; 235(1):45-52. PubMed ID: 2864253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time course and clinical predictors of treatment response in schizophrenia.
    Harvey PD; Davidson M; Powchik P; Schmeidler J; McQueeney R; Kaminsky R; Davis KL
    Schizophr Res; 1991 Sep; 5(2):161-6. PubMed ID: 1931808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal drug and behavior therapy for treatment-refractory institutionalized schizophrenics.
    Kuehnel TG; Liberman RP; Marshall BD; Bowen L
    New Dir Ment Health Serv; 1992; (53):67-78. PubMed ID: 1349727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical neuroleptic tests in the case of the butyrophenone derivatives benzperidol and spiroperidol].
    Haase HJ; Mattke D; Schönbeck M
    Psychopharmacologia; 1964 Dec; 6(6):435-52. PubMed ID: 5830963
    [No Abstract]   [Full Text] [Related]  

  • 39. Pre-morbid asociality in neuroleptic-resistant and neuroleptic-responsive schizophrenia.
    Findling RL; Jayathilake K; Meltzer HY
    Psychol Med; 1996 Sep; 26(5):1033-41. PubMed ID: 8878335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leukocyte adhesiveness/aggregation and neuroleptic drug treatment.
    Zemishlany Z; Aizenberg D; Baruch Y; Aronson M
    Int Clin Psychopharmacol; 1991; 6(2):111-5. PubMed ID: 1683666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.